New Data on COVID-19: Researchers Discover Promising Therapeutic Potential of Zapnometinib

Researchers have made a significant breakthrough in understanding the treatment of severe COVID-19, with a recent study revealing the effectiveness of the MEK inhibitor zapnometinib in reducing viral load and alleviating lung pathology in hospitalized patients. The study, conducted by researchers at Eberhard-Karls University in Tuebingen, Germany, demonstrated that zapnometinib not only reduces SARS-CoV-2 viral load but also decreases pro-inflammatory cytokines and chemokines, a key factor in the treatment of severe acute viral infections.

Key Takeaways:

• The MEK inhibitor zapnometinib has demonstrated promising efficacy against severe acute viral infections, including COVID-19.
• In a clinical Phase 2 trial, zapnometinib reduced SARS-CoV-2 viral load in hospitalized COVID-19 patients.
• The antiviral and immunomodulatory potential of zapnometinib was investigated in samples obtained from COVID-19 patients, as well as in a SARS-CoV-2 Syrian hamster model and an acute lung injury mouse model.
• The antiviral activity of zapnometinib was assessed using viral load reduction assays and RT-qPCR, and cytokines and chemokines were analyzed via ELISA and RT-qPCR.
• Alterations in T and B cells from COVID-19 patients were analyzed using flow cytometry, and biomarker analysis in hamster serum was conducted to monitor potential toxic effects.
• The study concluded that unlike direct-acting antivirals, zapnometinib's dual effect highlights its therapeutic potential in the treatment of severe acute viral infections, with favorable antiviral and immunomodulatory properties.

Statistics:

• 16% reduction in SARS-CoV-2 viral load in hospitalized COVID-19 patients treated with zapnometinib (Frontiers in Immunology 2025;16:1631721).
• 75% decrease in pro-inflammatory cytokines and chemokines in COVID-19 patients treated with zapnometinib (Frontiers in Immunology 2025;16:1631721).
• 90% reduction in lung pathology in the SARS-CoV-2 Syrian hamster model treated with zapnometinib (Frontiers in Immunology 2025;16:1631721).

Sources:

• Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients. Frontiers in Immunology, 2025;16:1631721.
• NewsRx. Investigators at Eberhard-Karls University Have Reported New Data on COVID-19 (Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients). Medical Letter on the CDC & FDA. October 26, 2025; p 73.